Skip to main content
Premium Trial:

Request an Annual Quote

Aviva Licenses Regulatory Gene-Mapping Tech from UCSD

NEW YORK, Feb. 1 (GenomeWeb News) - Aviva Systems Biology has licensed the rights to develop and commercialize products based on Gene Regulation Elements Mapping and Analysis (GREMA) technology from the University of California, San Diego, the company said today.

 

GREMA, developed by UCSD professor of cellular and molecular biology Xiangdong Fu, is a method for detecting DNA fragments, such as promoters, that interact with proteins, Aviva said.

 

Aviva has used its bioinformatics platform to identify approximately 32,000 potential promoter sequences, 20,000 of which it has incorporated into a DNA microarray to be sold to the basic research market.

 

According to a company representative, Aviva has essentially developed the chip, and hopes to launch the product in about two months.

The Scan

Shape of Them All

According to BBC News, researchers have developed a protein structure database that includes much of the human proteome.

For Flu and More

The Wall Street Journal reports that several vaccine developers are working on mRNA-based vaccines for influenza.

To Boost Women

China's Ministry of Science and Technology aims to boost the number of female researchers through a new policy, reports the South China Morning Post.

Science Papers Describe Approach to Predict Chemotherapeutic Response, Role of Transcriptional Noise

In Science this week: neural network to predict chemotherapeutic response in cancer patients, and more.